Avelumab

Generic Name
Avelumab
Brand Names
Bavencio
Drug Type
Biotech
Chemical Formula
-
CAS Number
1537032-82-8
Unique Ingredient Identifier
KXG2PJ551I
Background

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...

Indication

Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...

Associated Conditions
Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
Associated Therapies
First Line Chemotherapy, Maintenance therapy

Avelumab Program Rollover Study

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-01-24
Last Posted Date
2024-11-08
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
205
Registration Number
NCT03815643
Locations
🇺🇸

Norwalk Hospital - The Whittingham Cancer Center, Norwalk, Connecticut, United States

🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

Highlands Oncology Group, Fayetteville, Arkansas, United States

and more 100 locations

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

First Posted Date
2019-01-23
Last Posted Date
2019-02-05
Lead Sponsor
Royal Marsden NHS Foundation Trust
Target Recruit Count
75
Registration Number
NCT03812796
Locations
🇬🇧

The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma

First Posted Date
2019-01-11
Last Posted Date
2021-09-08
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
26
Registration Number
NCT03800953
Locations
🇨🇳

National Taiwan University Hospital, Taiwan, Taipei, Taiwan

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2018-12-26
Last Posted Date
2023-03-02
Lead Sponsor
Kartos Therapeutics, Inc.
Target Recruit Count
115
Registration Number
NCT03787602
Locations
🇫🇷

CHU de Bordeaux- Hopital Saint-Andre, Bordeaux, France

🇫🇷

Hôpital de la Timone. Aix-Marseille Université, Marseille, France

🇫🇷

CHU Montpellier, Montpellier, France

and more 48 locations

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

First Posted Date
2018-12-21
Last Posted Date
2023-12-19
Lead Sponsor
Ashwin Somasundaram
Target Recruit Count
18
Registration Number
NCT03783936
Locations
🇺🇸

University of Iowa Hospital and Clinics, Iowa City, Iowa, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 4 locations

Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

First Posted Date
2018-12-13
Last Posted Date
2023-04-21
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
32
Registration Number
NCT03774901
Locations
🇫🇷

Antoine THIERY VUILLEMIN, Besançon, France

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

First Posted Date
2018-12-10
Last Posted Date
2024-07-09
Lead Sponsor
Jodi Layton, MD
Target Recruit Count
8
Registration Number
NCT03770455
Locations
🇺🇸

Tulane University School of Medicine, New Orleans, Louisiana, United States

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

First Posted Date
2018-11-20
Last Posted Date
2024-11-27
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
24
Registration Number
NCT03747419
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

First Posted Date
2018-11-20
Last Posted Date
2024-10-29
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
7
Registration Number
NCT03747484
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath